Literature DB >> 35606577

Microcirculation-guided treatment improves tissue perfusion and hemodynamic coherence in surgical patients with septic shock.

Athanasios Chalkias1,2,3,4, Eleni Laou5, Maria Mermiri5, Anastasia Michou5, Nicoleta Ntalarizou5, Stamatia Koutsona5, Georgios Chasiotis6, Grigorios Garoufalis7, Vasileios Agorogiannis7, Aikaterini Kyriakaki5, Nikolaos Papagiannakis8.   

Abstract

PURPOSE: Severe sepsis and septic shock may impair microcirculatory perfusion and cause organ dysfunction. The aim of this pilot study was to assess a new microcirculation-guided resuscitation strategy in patients with septic shock undergoing emergency abdominal surgery.
METHODS: A microcirculation-guided treatment algorithm was developed and applied intraoperatively following restoration of systemic hemodynamics. Sublingual microcirculation was monitored with Sidestream DarkField (SDF +) imaging technique. The primary objective was to investigate the change in De Backer score, Consensus Proportion of Perfused Vessels (Consensus PPV), and Consensus PPV (small) and its association with venous-to-arterial carbon dioxide difference (v-aPCO2).
RESULTS: Thirteen consecutive patients were included in the study. Microcirculation-guided resuscitation resulted in an increase of 0.49 mm-1 in the De Backer score (p < 0.001), an increase of 2.28% in the Consensus PPV (p < 0.001), and an increase of 2.26% in the Consensus PPV (small) (p < 0.001) for every 30 min of additional intraoperative time. All microcirculation variables were negatively correlated with v-aPCO2 (rho = - 0.656, adj-p < 0.001; rho = - 0.623; adj-p < 0.001; rho = - 0.597, adj-p < 0.001, respectively) at each intraoperative time point. Lactate levels were negatively correlated with Consensus PPV (rho = - 0.464; adj-p = 0.002) and Consensus PPV (small) (rho = - 0.391, adj-p < 0.001). Survival at 30 days, 90 days, and 1 year were 76.9%, 76.9%, and 61.5%, respectively.
CONCLUSIONS: The intraoperative use of microcirculation-guided resuscitation strategy may improve tissue perfusion and hemodynamic coherence in patients with septic shock.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Critical care; Emergency surgery; Microcirculation; Resuscitation; Septic shock; Tissue perfusion

Year:  2022        PMID: 35606577     DOI: 10.1007/s00068-022-01991-2

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  1 in total

1.  Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE).

Authors:  Athanasios Chalkias; Eleni Laou; Konstantina Kolonia; Dimitrios Ragias; Zacharoula Angelopoulou; Eleni Mitsiouli; Thomas Kallemose; Lars Smith-Hansen; Jesper Eugen-Olsen; Eleni Arnaoutoglou
Journal:  Surgery       Date:  2021-11-01       Impact factor: 3.982

  1 in total
  3 in total

1.  Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Athanasios Chalkias; Nikolaos Papagiannakis; Bernd Saugel; Moritz Flick; Konstantina Kolonia; Zacharoula Angelopoulou; Dimitrios Ragias; Dimitra Papaspyrou; Aikaterini Bouzia; Nicoletta Ntalarizou; Konstantinos Stamoulis; Aikaterini Kyriakaki; Jesper Eugen-Olsen; Eleni Laou; Eleni Arnaoutoglou
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Current Challenges in the Management of Sepsis and Septic Shock: Personalized, Physiology-Guided Treatment.

Authors:  Athanasios Chalkias
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

3.  Relationship of Effective Circulating Volume with Sublingual Red Blood Cell Velocity and Microvessel Pressure Difference: A Clinical Investigation and Computational Fluid Dynamics Modeling.

Authors:  Athanasios Chalkias; Michalis Xenos
Journal:  J Clin Med       Date:  2022-08-20       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.